Sam Brusco, Associate Editor12.13.22
Eli Lilly has stopped a joint project with Ypsomed to enter the U.S. insulin pump market in 2026 in order to fully focus on its drug portfolio. Ypsomed aims to submit its YpsoPump system to the FDA in the second half of 2023 according to plan and subsequently market the system with a new partner.
Ypsomed and Eli Lilly began the agreement in November 2020 to register and commercialize YpsoPump under Lilly’s brand in the U.S. During the last two years Ypsomed has tailored its insulin pump for the U.S. market and the company remains committed to the U.S. market. Ypsomed will be deepening discussions with other interested parties.
YpsoPump is attractive in the U.S. market thanks to its form factors, prefilled cartridge, and proven automated insulin delivery system. The commercial success of the company’s mylife Loop with YpsoPump in Europe has demonstrated its high acceptance among diabetes patients.
Ypsomed and Eli Lilly began the agreement in November 2020 to register and commercialize YpsoPump under Lilly’s brand in the U.S. During the last two years Ypsomed has tailored its insulin pump for the U.S. market and the company remains committed to the U.S. market. Ypsomed will be deepening discussions with other interested parties.
YpsoPump is attractive in the U.S. market thanks to its form factors, prefilled cartridge, and proven automated insulin delivery system. The commercial success of the company’s mylife Loop with YpsoPump in Europe has demonstrated its high acceptance among diabetes patients.